Moonshot, DeepSeek, and the Great Chinese AI IPO Rush Is Reshaping Global Tech Capital Markets

Two Chinese AI companies are accelerating toward public markets with valuations that did not exist six months ago, as Kimi K3 and DeepSeek's open-weight models force a recalculation of what Chinese frontier labs are worth.

Moonshot AI is preparing for a Hong Kong listing within six months at a valuation between $30 billion and $50 billion, according to Nikkei Asia and multiple other reports. The company's valuation has ballooned from roughly $4 billion at the end of 2025 to somewhere between $20 billion and $30 billion in its latest financing round, which pulled in approximately $2 billion.

DeepSeek is moving in parallel. The Hangzhou-based startup has begun IPO preparations with a potential filing targeted for late 2026 and a listing in 2027, Bloomberg reported. Reuters said DeepSeek is raising fresh capital at a $74 billion valuation ahead of the onshore IPO. Both companies are targeting domestic exchanges: Hong Kong for Moonshot, mainland China for DeepSeek.

The catalyst in both cases is model performance that surprised Western labs. Kimi K3 launched July 16 as an open-weight model, immediately triggering a subscription surge that forced Moonshot to temporarily halt new signups. The model wiped an estimated $3.3 trillion from semiconductor stocks as markets repriced the implication that frontier performance does not require Nvidia's latest silicon.

DeepSeek's open-weight releases have demonstrated similar cost efficiency, reportedly matching Western frontier performance at substantially lower inference cost. The company's $74 billion valuation places it in the same tier as Anthropic's pre-IPO numbers, though the comparison is imperfect: DeepSeek operates under a different cost structure and regulatory framework.

Both companies face US government scrutiny. The White House this week accused Moonshot of illicitly distilling Anthropic's Fable model to build Kimi K3. Treasury Secretary Scott Bessent warned of sanctions. DeepSeek has faced similar allegations. The Entity List risk is real and unquantified in any valuation model.

The pricing implications extend beyond these two names. If Moonshot lists on the Hong Kong Stock Exchange at $30 billion plus and trades well, every Chinese AI startup with frontier-model ambitions sees its funding path widen. If the stock trades down, the signal reverses: public markets will not pay Western multiples for Chinese AI companies operating under active US sanctions risk.

The unresolved edge is timing. Moonshot is targeting a listing within six months. If the US imposes sanctions during the quiet period, the IPO pauses. If Kimi K3 benchmarks are independently verified as competitive with Claude and GPT across a broad suite, the valuation holds. Neither condition is certain.

CXMT, China's largest memory chipmaker, is also preparing an $8.5 billion IPO, adding hardware to the software listings that are beginning to stack up. The Chinese AI capital markets story is no longer about one company or one model. It is a pipeline.

Source